Anna Lena LopezJacqueline DeenAndrew S. AzmanFrancisco J. LuqueroSuman KanungoShanta DuttaLorenz Von SeidleinDavid A. SackUniversity of the Philippines SystemEpicentreMahidol UniversityNational Institute of Cholera and Enteric Diseases IndiaJohns Hopkins University2019-08-282019-08-282018-06-01Clinical Infectious Diseases. Vol.66, No.12 (2018), 1960-197115376591105848382-s2.0-85048005104https://repository.li.mahidol.ac.th/handle/20.500.14594/46643© 2017 The Author(s). In addition to improved water supply and sanitation, the 2-dose killed oral cholera vaccine (OCV) is an important tool for the prevention and control of cholera. We aimed to document the immunogenicity and protection (efcacy and effectiveness) conferred by a single OCV dose against cholera. Te metaanalysis showed that an estimated 73% and 77% of individuals seroconverted to the Ogawa and Inaba serotypes, respectively, afer an OCV frst dose. Te estimates of single-dose vaccine protection from available studies are 87% at 2 months decreasing to 33% at 2 years. Current immunologic and clinical data suggest that protection conferred by a single dose of killed OCV may be sufcient to reduce short-term risk in outbreaks or other high-risk settings, which may be especially useful when vaccine supply is limited. However, until more data suggest otherwise, a second dose should be given as soon as circumstances allow to ensure robust protection.Mahidol UniversityMedicineReviewSCOPUS10.1093/cid/cix1039